Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib/II Study of Epacadostat (INCB024360) and Pembrolizumab Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

Trial Profile

Phase Ib/II Study of Epacadostat (INCB024360) and Pembrolizumab Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2018

At a glance

  • Drugs Epacadostat (Primary) ; Pembrolizumab (Primary) ; Capecitabine; Oxaliplatin
  • Indications Rectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Nov 2018 Planned End Date changed from 31 May 2022 to 31 Aug 2022.
    • 13 Nov 2018 Planned primary completion date changed from 31 May 2022 to 31 Aug 2022.
    • 13 Nov 2018 Planned initiation date changed from 31 Oct 2018 to 31 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top